Hormonal
Semaglutide 2.4 mg/week significantly reduces major adverse cardiovascular events (MACE) in overweight or obese adults with preexisting cardiovascular disease but without diabetes.
If you are overweight or obese and have existing heart disease but no diabetes, ask your doctor about semaglutide 2.4 mg/week. It is the first obesity medication proven to lower the risk of heart attacks, strokes, and cardiovascular death. The treatment involves a weekly injection, starting at a low dose to minimize stomach issues, and has been shown to significantly improve cardiovascular outcomes over standard care alone.
In conclusion, semaglutide is the first anti-obesity agent shown to decrease CV events in overweight/obese subjects with CV disease without diabetes.
Why this rating
Based on the SELECT trial, a large (n=17,604), multinational, randomized, placebo-controlled, double-blind megatrial.
Source
Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events
Nasser Mikhail et al. · Annals of Cardiovascular Diseases · 2024
DOI 10.47739/2641-7731.cardiovasculardiseases.1036
More from this paper
- Semaglutide 2.4 mg/week leads to significant weight loss and improvement in cardiovascular risk factors (blood pressure, lipids, inflammation) in overweight or obese adults without diabetes.Strong
- Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →